1. New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao Blood Volume 125(20):3059-3068 May 14, 2015 ©2015 by American Society of Hematology

2. Graphical representation of the increasing number of publications in PUBMED and abstracts reported in the Annual Congress of the American Society of Hematology (ASH) on MM MRD during the past decades. Bruno Paiva et al. Blood 2015;125:3059-3068 ©2015 by American Society of Hematology

3. Schematic representation to illustrate the paradigm of the deeper the response, the longer the (progression-free) survival (filled lines). Bruno Paiva et al. Blood 2015;125:3059-3068 ©2015 by American Society of Hematology

4. Number of studies published in PUBMED per MRD technique showing prognostic value for progression-free survival (PFS) and overall survival (OS) specifically among patients in CR after therapy. Bruno Paiva et al. Blood 2015;125:3059-3068 ©2015 by American Society of Hematology

5. MRD monitoring (ie, black solid line arrows) has been reported (numbers refer to the literature cited in the present review) to be prognostically informative among cytogenetically defined standard- and high-risk MM patients after induction chemotherapy, HDT... Bruno Paiva et al. Blood 2015;125:3059-3068 ©2015 by American Society of Hematology